Errichetti, E. (2024) “Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial”, Acta Dermato-Venereologica, 104, p. adv41053. doi: 10.2340/actadv.v104.41053.